A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis
Pauline T. Lukey, Stephen A. Harrison, Shuying Yang, Yim Man, Beverley F. Holman, Alaleh Rashidnasab, Gabrielle Azzopardi, Michael Grayer, Juliet K. Simpson, Philippe Bareille, Lyn Paul, Hannah V. Woodcock, Richard Toshner, Peter Saunders, Philip L. Molyneaux, Kris Thielemans, Frederick J. Wilson, Paul F. Mercer, Rachel C. Chambers, Ashley M. Groves, William A. Fahy, Richard P. Marshall, Toby M. Maher
Source: Eur Respir J, 53 (3) 1801992; 10.1183/13993003.01992-2018
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Pauline T. Lukey, Stephen A. Harrison, Shuying Yang, Yim Man, Beverley F. Holman, Alaleh Rashidnasab, Gabrielle Azzopardi, Michael Grayer, Juliet K. Simpson, Philippe Bareille, Lyn Paul, Hannah V. Woodcock, Richard Toshner, Peter Saunders, Philip L. Molyneaux, Kris Thielemans, Frederick J. Wilson, Paul F. Mercer, Rachel C. Chambers, Ashley M. Groves, William A. Fahy, Richard P. Marshall, Toby M. Maher. A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis. Eur Respir J, 53 (3) 1801992; 10.1183/13993003.01992-2018
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772) Source: Eur Respir J, 52 (6) 1801130; 10.1183/13993003.01130-2018 Year: 2018
RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021
A randomized, double-blind, placebo-controlled, phase III study of the safety and efficacy of interferon gamma-1b in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2007 - Clinical trial: new biological approaches to respiratory diseases Year: 2007
Azithromycin for the treatment of cough in idiopathic pulmonary fibrosis: A randomized controlled cross-over pilot trial. Source: Virtual Congress 2020 – Chronic cough: only symptom or disease? Year: 2020
Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial Source: Eur Respir J 2013; 42: 1622-1632 Year: 2013
Recent clinical trials in idiopathic pulmonary fibrosis and the BUILD-1 study Source: Eur Respir Rev 2008; 17: 116-122 Year: 2008
A feasibility, randomised controlled trial of a complex breathlessness intervention in idiopathic pulmonary fibrosis (BREEZE-IPF): study protocol Source: ERJ Open Res, 5 (4) 00186-2019; 10.1183/23120541.00186-2019 Year: 2019
Preliminary results of a prospective, multicentric randomized study comparing Interferon Gamma-1b (IFN-γ) and colchicine in the treatment of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2003 - Interstitial lung diseases Year: 2003
A prospective randomised double-blind placebo controlled trial of venlafaxine in patients with stable chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 32s Year: 2006
LATE-BREAKING ABSTRACT: COPD-associated severe pulmonary hypertension (COPDPH): results of a 16-weeks prospective multicenter, double-blind, placebo-controlled randomized clinical trial (RCT) [SPHERIC-1 (http://clinicaltrials.gov/ct2/show/NCT01441934)] investigating the effect of sildenafil citrate (Sld) on pulmonary vascular resistance (PVR) and PaO2. Source: Annual Congress 2013 –Pulmonary circulation: basic science Year: 2013
Late Breaking Abstract - Phase 2, multi-center, open label, single-arm study of TAS-115, a novel multi-kinase inhibitor in patients with idiopathic pulmonary fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019
Oral sildenafil treatment in children with pulmonary arterial hypertension (PAH): results of a double-blind, placebo-controlled, dose-ranging study Source: Annual Congress 2009 - Clinical Trials: "Aerosolized Lancovutide (Moli1901)" and "Oral Sildenafil" Year: 2009
Oral sildenafil treatment in children with pulmonary arterial hypertension (PAH): results of a double-blind, placebo-controlled, dose-ranging study Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009
Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Source: Eur Respir J 2002; 20: 245 Year: 2002
A multicentre randomised controlled trial of inspiratory muscle training for patients with chronic obstructive pulmonary disease (IMTCO study) Source: International Congress 2017 – Exercise training and breathing exercises in chronic respiratory disease Year: 2017
PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017
Design of phase II, randomized, placebo-controlled study of loratadine associate with rapamycin in patients with lymphangioleiomyomatosis (LAM) Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020
Pulmonary vasodilator therapy in severe COPD: a double-blind, placebo-controlled trial Source: Eur Respir J 2007; 30: Suppl. 51, 525s Year: 2007
The use of modafinil in patients with obstructive apnoea-hyponoea syndrome (OAHS). A randomized, placebo-controlled, double-blind study Source: Eur Respir J 2001; 18: Suppl. 33, 419s Year: 2001
Comparison of Interferon gamma-1b (IFN-γ)and colcicine in the treatment of Idiopathic pulmonary fibrosis: preliminary results of a prospective, multicenter randomised study Source: Eur Respir J 2002; 20: Suppl. 38, 599s Year: 2002